<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157842</url>
  </required_header>
  <id_info>
    <org_study_id>1900025501</org_study_id>
    <nct_id>NCT04157842</nct_id>
  </id_info>
  <brief_title>The Influence of Hip Replacement on Lower Extremity Hemodynamics in Crowe IV Hip Dysplasia Patient</brief_title>
  <official_title>The Influence of Hip Replacement (Subtrochanteric Osteotomy vs. Non-osteotomy) on Lower Extremity Hemodynamics in Crowe IV Hip Dysplasia Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the influence of hip replacement on lower extremity hemodynamics in Crowe Ⅳ hip
      dysplasia patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Changes of limb length after total hip replacement is common, especially for Crowe Ⅳ hip
      dysplasia patient. Such change potentially increases tension of vessel and influence lower
      extremity hemodynamics. Till now, little is known in this area.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hip Harris Score</measure>
    <time_frame>preoperative, 1 week, 6 weeks, 12 weeks, 24 weeks and 1 year after the surgery.</time_frame>
    <description>change of hip harris score scale from baseline(preoperative) to 1 year after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Length Change</measure>
    <time_frame>preoperative, 1 week, 6 weeks, 12 weeks, 24 weeks and 1 year after the surgery.</time_frame>
    <description>change of Leg Length from baseline(preoperative) to 1 year after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Results</measure>
    <time_frame>1 week, 12 weeks, 24 weeks and 1 year after the surgery.</time_frame>
    <description>change of Radiographic Results from 1 week after surger to 1 year after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lower Limb Arterial CT Angiography</measure>
    <time_frame>preoperative, 1 week, 12 weeks after the surgery.</time_frame>
    <description>change of vascular diameter and vascular cross-sectional from baseline(preoperative) to 1 year after surgery baseline(preoperative) to 12 weeks after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Ultrasound Examination</measure>
    <time_frame>preoperative, 1 week, 6 weeks, 12 weeks, 24 weeks and 1 year after the surgery.</time_frame>
    <description>change of systolic peak velocity, end-diastolic velocity, pulsation index, resistance index and blood flow from baseline(preoperative) to 1 year after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Viscosity</measure>
    <time_frame>preoperative, 1 week, 6 weeks, 12 weeks, 24 weeks and 1 year after the surgery.</time_frame>
    <description>change of blood viscosity from baseline(preoperative) to 1 year after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hip Dysplasia</condition>
  <arm_group>
    <arm_group_label>total hip replacement with subtrochanteral osteotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subtrochanteral osteotomy is applied during total hip replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>total hip replacement with no osteotomy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>no osteotomy is applied during total hip replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>total hip replacement with subtrochanteral osteotomy</intervention_name>
    <description>applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve</description>
    <arm_group_label>total hip replacement with subtrochanteral osteotomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>total hip replacement with no osteotomy</intervention_name>
    <description>just total hip replacement</description>
    <arm_group_label>total hip replacement with no osteotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral Crow IV hip dysplasia;

          -  Bilateral Crow IV hip dysplasia without osteoarthritis on the other side

        Exclusion Criteria:

          -  Patients with serious medical disease;

          -  Patients with lower extremity vascular disease; 3. Patients with severe mental
             illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SHIGUI YAN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>2nd affiliated hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SHIGUI YAN, MD</last_name>
    <phone>+86-13906531308</phone>
    <email>zrjwsj@zju.edu.cn</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

